Efficacy and Safety of Tofacitinib for Acute Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Gastroenterology Res · 2025 · PMC12758076 · PMID 41488821

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendP = 0.08so close (0.05 < p ≤ 0.1)

Additionally, tofacitinib showed a trend toward a reduced 90-day colectomy rate compared to the control group (P = 0.08).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.